 Holly Frost
Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Otitis Media | 14 | 2024 | 160 | 8.530 |
Why?
| | Anti-Bacterial Agents | 29 | 2024 | 1671 | 5.670 |
Why?
| | Antimicrobial Stewardship | 9 | 2024 | 99 | 3.970 |
Why?
| | Conjunctivitis | 7 | 2024 | 29 | 3.900 |
Why?
| | Gonorrhea | 5 | 2023 | 57 | 3.600 |
Why?
| | Chlamydia Infections | 5 | 2023 | 74 | 3.570 |
Why?
| | Conjunctivitis, Bacterial | 4 | 2024 | 11 | 2.960 |
Why?
| | Haemophilus influenzae | 3 | 2024 | 62 | 1.990 |
Why?
| | Practice Patterns, Physicians' | 10 | 2024 | 1269 | 1.970 |
Why?
| | Acute Disease | 12 | 2024 | 968 | 1.850 |
Why?
| | Amoxicillin | 3 | 2024 | 30 | 1.820 |
Why?
| | Lyme Disease | 4 | 2018 | 50 | 1.720 |
Why?
| | Respiratory Tract Infections | 4 | 2022 | 372 | 1.690 |
Why?
| | Child | 35 | 2024 | 20805 | 1.540 |
Why?
| | Blastomycosis | 3 | 2024 | 9 | 1.270 |
Why?
| | Encephalitis Viruses, Tick-Borne | 2 | 2020 | 8 | 1.250 |
Why?
| | Encephalitis, Tick-Borne | 2 | 2020 | 8 | 1.240 |
Why?
| | Pharyngitis | 2 | 2018 | 24 | 1.210 |
Why?
| | Haemophilus Infections | 2 | 2024 | 38 | 1.120 |
Why?
| | Blastomyces | 3 | 2024 | 8 | 1.110 |
Why?
| | Otitis | 2 | 2024 | 9 | 1.100 |
Why?
| | Drug Prescriptions | 2 | 2020 | 250 | 1.090 |
Why?
| | Sinusitis | 2 | 2019 | 202 | 1.030 |
Why?
| | Syphilis | 2 | 2024 | 32 | 0.970 |
Why?
| | Infant | 12 | 2024 | 8992 | 0.900 |
Why?
| | Humans | 52 | 2024 | 129126 | 0.890 |
Why?
| | Child, Preschool | 14 | 2024 | 10450 | 0.890 |
Why?
| | Chlamydia | 1 | 2023 | 9 | 0.830 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2023 | 48 | 0.810 |
Why?
| | Guideline Adherence | 3 | 2022 | 525 | 0.810 |
Why?
| | Ambulatory Care | 2 | 2023 | 506 | 0.770 |
Why?
| | Wisconsin | 5 | 2020 | 101 | 0.760 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 582 | 0.740 |
Why?
| | Sexually Transmitted Diseases | 1 | 2023 | 150 | 0.710 |
Why?
| | Endemic Diseases | 2 | 2018 | 30 | 0.690 |
Why?
| | Bacterial Infections | 2 | 2020 | 229 | 0.680 |
Why?
| | Papillomavirus Vaccines | 1 | 2023 | 230 | 0.670 |
Why?
| | Methylprednisolone | 1 | 2020 | 82 | 0.660 |
Why?
| | Adolescent | 15 | 2024 | 20301 | 0.650 |
Why?
| | Time-to-Treatment | 1 | 2021 | 180 | 0.650 |
Why?
| | Papillomavirus Infections | 1 | 2023 | 291 | 0.640 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 256 | 0.640 |
Why?
| | Streptococcus | 1 | 2018 | 25 | 0.620 |
Why?
| | Infectious Mononucleosis | 1 | 2018 | 9 | 0.610 |
Why?
| | Anaplasmosis | 1 | 2018 | 1 | 0.610 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1493 | 0.600 |
Why?
| | Primary Health Care | 4 | 2023 | 1641 | 0.570 |
Why?
| | Babesiosis | 1 | 2017 | 2 | 0.570 |
Why?
| | Antiprotozoal Agents | 1 | 2017 | 12 | 0.570 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 194 | 0.560 |
Why?
| | Chlamydia trachomatis | 3 | 2022 | 47 | 0.560 |
Why?
| | Outpatients | 4 | 2022 | 367 | 0.560 |
Why?
| | Program Evaluation | 1 | 2021 | 876 | 0.550 |
Why?
| | Streptococcal Infections | 1 | 2018 | 145 | 0.530 |
Why?
| | Male | 20 | 2024 | 63201 | 0.520 |
Why?
| | Inpatients | 1 | 2020 | 464 | 0.500 |
Why?
| | Antibodies, Fungal | 1 | 2015 | 9 | 0.500 |
Why?
| | Antigens, Fungal | 1 | 2015 | 26 | 0.500 |
Why?
| | Female | 20 | 2024 | 68517 | 0.490 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 3 | 2024 | 14 | 0.480 |
Why?
| | Drug Administration Schedule | 3 | 2024 | 758 | 0.460 |
Why?
| | Retrospective Studies | 10 | 2024 | 14571 | 0.450 |
Why?
| | Rubulavirus Infections | 1 | 2013 | 2 | 0.440 |
Why?
| | Genotype | 2 | 2024 | 1832 | 0.420 |
Why?
| | Weight Reduction Programs | 2 | 2024 | 111 | 0.390 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1098 | 0.390 |
Why?
| | Colorado | 5 | 2024 | 4396 | 0.390 |
Why?
| | Neisseria gonorrhoeae | 2 | 2022 | 24 | 0.370 |
Why?
| | Pediatric Obesity | 3 | 2024 | 572 | 0.370 |
Why?
| | Physicians | 1 | 2020 | 861 | 0.360 |
Why?
| | Seroepidemiologic Studies | 2 | 2023 | 156 | 0.340 |
Why?
| | Electronic Health Records | 4 | 2024 | 976 | 0.330 |
Why?
| | Inappropriate Prescribing | 2 | 2021 | 53 | 0.320 |
Why?
| | Pandemics | 3 | 2022 | 1491 | 0.320 |
Why?
| | United States | 6 | 2024 | 13939 | 0.320 |
Why?
| | Doxycycline | 2 | 2020 | 55 | 0.310 |
Why?
| | HIV Infections | 2 | 2024 | 2715 | 0.290 |
Why?
| | Mass Screening | 3 | 2024 | 1159 | 0.260 |
Why?
| | Antibodies, Viral | 2 | 2023 | 603 | 0.260 |
Why?
| | Young Adult | 5 | 2024 | 12389 | 0.250 |
Why?
| | Ambulatory Care Facilities | 3 | 2024 | 227 | 0.240 |
Why?
| | Treatment Outcome | 3 | 2024 | 10226 | 0.240 |
Why?
| | Prevalence | 2 | 2023 | 2564 | 0.240 |
Why?
| | Administration, Ophthalmic | 1 | 2024 | 14 | 0.230 |
Why?
| | Child Care | 1 | 2024 | 26 | 0.230 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 73 | 0.220 |
Why?
| | beta-Lactamases | 1 | 2024 | 34 | 0.220 |
Why?
| | Absenteeism | 1 | 2024 | 49 | 0.220 |
Why?
| | Interrupted Time Series Analysis | 1 | 2023 | 52 | 0.210 |
Why?
| | Quality Improvement | 2 | 2021 | 1099 | 0.210 |
Why?
| | Nasopharynx | 1 | 2023 | 67 | 0.210 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2023 | 51 | 0.210 |
Why?
| | Family Characteristics | 1 | 2024 | 179 | 0.200 |
Why?
| | Adult | 6 | 2024 | 35512 | 0.200 |
Why?
| | Age Factors | 2 | 2020 | 3120 | 0.190 |
Why?
| | Pneumococcal Vaccines | 1 | 2023 | 139 | 0.190 |
Why?
| | Azithromycin | 1 | 2022 | 91 | 0.190 |
Why?
| | Streptococcus pneumoniae | 1 | 2023 | 159 | 0.190 |
Why?
| | Sexual Health | 1 | 2022 | 54 | 0.190 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2021 | 20 | 0.190 |
Why?
| | Academic Medical Centers | 1 | 2024 | 479 | 0.190 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1363 | 0.180 |
Why?
| | Urban Health | 1 | 2021 | 79 | 0.180 |
Why?
| | Focus Groups | 1 | 2023 | 455 | 0.180 |
Why?
| | Schools | 1 | 2024 | 439 | 0.180 |
Why?
| | Text Messaging | 1 | 2022 | 149 | 0.170 |
Why?
| | Follow-Up Studies | 2 | 2022 | 4915 | 0.170 |
Why?
| | Decision Support Techniques | 1 | 2024 | 405 | 0.170 |
Why?
| | Private Sector | 1 | 2020 | 51 | 0.170 |
Why?
| | Homosexuality, Male | 1 | 2021 | 176 | 0.160 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 305 | 0.160 |
Why?
| | Drug Utilization | 1 | 2020 | 167 | 0.160 |
Why?
| | Practice Patterns, Nurses' | 1 | 2018 | 19 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2021 | 862 | 0.140 |
Why?
| | Babesia | 1 | 2017 | 3 | 0.140 |
Why?
| | Tick Bites | 1 | 2017 | 4 | 0.140 |
Why?
| | Insurance, Health | 1 | 2020 | 271 | 0.140 |
Why?
| | Family Practice | 1 | 2021 | 435 | 0.140 |
Why?
| | Lung Diseases, Fungal | 1 | 2017 | 12 | 0.140 |
Why?
| | Public Health | 1 | 2022 | 486 | 0.140 |
Why?
| | Case-Control Studies | 1 | 2024 | 3342 | 0.140 |
Why?
| | Physician Assistants | 1 | 2018 | 89 | 0.140 |
Why?
| | Physicians, Family | 1 | 2018 | 203 | 0.130 |
Why?
| | Bacteria | 1 | 2023 | 811 | 0.130 |
Why?
| | Pediatricians | 1 | 2018 | 132 | 0.130 |
Why?
| | Interviews as Topic | 1 | 2020 | 716 | 0.130 |
Why?
| | Delayed Diagnosis | 1 | 2017 | 79 | 0.130 |
Why?
| | Nurse Practitioners | 1 | 2018 | 127 | 0.130 |
Why?
| | Immunoglobulin M | 1 | 2017 | 272 | 0.130 |
Why?
| | Internal Medicine | 1 | 2018 | 246 | 0.130 |
Why?
| | Immunologic Tests | 1 | 2015 | 16 | 0.130 |
Why?
| | Disease Reservoirs | 1 | 2015 | 19 | 0.120 |
Why?
| | Ticks | 1 | 2015 | 17 | 0.120 |
Why?
| | Emergency Medicine | 1 | 2018 | 227 | 0.120 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3033 | 0.120 |
Why?
| | Antifungal Agents | 1 | 2015 | 126 | 0.120 |
Why?
| | Vaccination | 1 | 2023 | 1349 | 0.110 |
Why?
| | Parainfluenza Virus 4, Human | 1 | 2013 | 2 | 0.110 |
Why?
| | Pediatrics | 1 | 2021 | 1062 | 0.110 |
Why?
| | Immunoglobulin G | 1 | 2017 | 846 | 0.100 |
Why?
| | Seasons | 1 | 2015 | 498 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2635 | 0.100 |
Why?
| | Cohort Studies | 1 | 2021 | 5407 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1825 | 0.090 |
Why?
| | Ecosystem | 1 | 2015 | 562 | 0.090 |
Why?
| | Prospective Studies | 1 | 2022 | 7079 | 0.080 |
Why?
| | Middle Aged | 3 | 2024 | 31079 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 1973 | 0.080 |
Why?
| | Risk Factors | 2 | 2024 | 9768 | 0.070 |
Why?
| | Aged | 2 | 2017 | 22089 | 0.070 |
Why?
| | Disease Progression | 1 | 2015 | 2613 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2018 | 5739 | 0.070 |
Why?
| | Health Promotion | 2 | 2023 | 718 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5070 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7065 | 0.060 |
Why?
| | Hotlines | 1 | 2024 | 32 | 0.060 |
Why?
| | Hospitals, General | 1 | 2024 | 21 | 0.060 |
Why?
| | Demography | 1 | 2024 | 277 | 0.060 |
Why?
| | Sexual Partners | 1 | 2024 | 185 | 0.050 |
Why?
| | Benchmarking | 1 | 2024 | 176 | 0.050 |
Why?
| | Reproductive Health | 1 | 2022 | 86 | 0.050 |
Why?
| | Educational Status | 1 | 2023 | 473 | 0.050 |
Why?
| | Sexual Behavior | 1 | 2022 | 483 | 0.040 |
Why?
| | Poverty | 1 | 2021 | 497 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2266 | 0.030 |
Why?
| | Animals | 1 | 2015 | 34600 | 0.030 |
Why?
| | Pregnancy | 1 | 2024 | 6375 | 0.020 |
Why?
|
|
Frost's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|